ArticleChinese medical journal pulmonary and critical care medicine2025
Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study.
Article in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The disease burden, treatment patterns, and financial costs associated with chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) remain poorly characterized, particularly in terms of real-world evidence derived from large populations. This study aimed to describe the incidence, treatment patterns, costs, and healthcare resource utilization (HCRU) in Chinese patients with ES-SCLC who develop CIM. Methods: Adults diagnosed with ES-SCLC who started etoposide-platinum (EP) chemotherapy for the first time between January 1, 2018 and December 31, 2022 were retrospectively identified in the Chinese National Cancer Information Database. Baseline demographic and clinical data were collected. Information on CIM-related events, treatment, costs, and HCRU during EP chemotherapy and during follow-up was assessed. Costs and HCRU were compared among patients with grade 3-4 CIM, grade 1-2 CIM, and no CIM using the Kruskal-Wallis test. Results: In total, 7505 patients with ES-SCLC (mean age 61.2 years; 17.7 % [1332/7505] female; body mass index 23.2±3.3 kg/m Conclusion: Despite the availability of supportive care for CIM in patients with ES-SCLC in China, a considerable clinical and financial burden persists. Strategies that protect bone marrow from progressing to high-grade myelosuppression could reduce the burden on patients and healthcare organizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.